LYEL Projected Dividend Yield
Lyell Immunopharma Inc ( NASDAQ : LYEL )Lyell Immunopharma, Inc. is a clinical-stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors. Co. is engaged in enrolling a Phase I clinical trial evaluating a ROR1-targeted CAR T-cell therapy in patients with relapsed refractory triple-negative breast cancer and non-small cell lung cancer (NSCLC) and a second Phase I clinical trial evaluating reprogrammed tumor infiltrating lymphocytes (TIL) in patients with advanced melanoma, NSCLC and colorectal cancer. 21 YEAR PERFORMANCE RESULTS |
LYEL Dividend History Detail LYEL Dividend News LYEL Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |